Akkan AVCİ, Mürsel KOÇER, Müge GÜLEN, Mehmet Oğuzhan AY, Ferhat ICME, Begüm Şeyda AVCİ

Oral Antikoagülan Tedaviye Sekonder Spontan Hemotoraks

Giriş: Oral antikoagülan kullanımına bağlı spontan hemotoraks görülmesi nadir bir komplikasyondur. Olgu Sunumu: Bu yazıda, acil servisimize nefes darlığı şikayeti ile başvuran ve warfarin kullanımına bağlı spontan hemotoraks saptanan 84 yaşındaki bir hastayı sunduk. Sonuç: Oral antikoagülan tedavi alan hastaların, etkin antikoagülan tedavinin sağlanabilmesi ve yan etkiler bakımından yakından takip edilmeleri ve bu hastalarda nefes darlığı gelişmesi halinde hemotoraksın ayırıcı tanıda akılda tutulması gerektiğini vurgulamayı amaçladık.

Anahtar Kelimeler:

Warfarin, hemotoraks, INR

Spontaneous Hemothorax Secondary to Oral Anticoagulation Therapy

Introduction: Occurrence of spontaneous hemothorax associated with the usage of oral anticoagulant is a rare complication.Case Report: In this paper, a case of an 84-year-old man who was admitted to the emergency department with dyspnea and in whom we detected spontaneous hemothorax due to warfarin was reported.Conclusion: Patients receiving oral anticoagulant treatment should be closely monitored for effective anticoagulation and adverse effects, and if dyspnea occurs, hemothorax should be considered in the differential diagnosis

Keywords:

Warfarin, hemothorax, INR,

PDF

___

Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med 2005; 45: 197-206. [CrossRef]
Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114: 511-23. [CrossRef]
Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8. [CrossRef]
Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et al. Managing oral anticoagulant therapy. Chest 2001; 119: 22-38. [CrossRef]
Landefeld CS, Beyth RJ. Anticoagulant-releated bleeding; clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-28. [CrossRef]
Doğan NÖ, Günaydın GP, Tekin M, Çevik Y. Nontraumatic massive spontaneous hemothorax with concomitant warfarin use. Case Rep Emerg Med 2013; article ID: 546024.
Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Seminars in Vascular Medicine 2003; 3: 271-8. [CrossRef]
Akay H. The diagnostic and therapeutic approach in hemothorax. Solunum 2002; 4: 195-205.
Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303. [CrossRef]
Mismetti P, Laporte S. Rivaroxaban: clinical pharmacology. Ann Fr Anesth Reanim 2008; 27: 16-21. [CrossRef]